201 related articles for article (PubMed ID: 31882225)
1. Implementation of Value-based Pricing for Medicines.
Jommi C; Armeni P; Costa F; Bertolani A; Otto M
Clin Ther; 2020 Jan; 42(1):15-24. PubMed ID: 31882225
[TBL] [Abstract][Full Text] [Related]
2. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
Ha SY; Kang DW; Jung HI; Lee EK; Park MH
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
[TBL] [Abstract][Full Text] [Related]
3. Convergence of decision rules for value-based pricing of new innovative drugs.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
[TBL] [Abstract][Full Text] [Related]
4. Operationalizing value-based pricing of medicines : a taxonomy of approaches.
Sussex J; Towse A; Devlin N
Pharmacoeconomics; 2013 Jan; 31(1):1-10. PubMed ID: 23329588
[TBL] [Abstract][Full Text] [Related]
5. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
6. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
Danzon PM
Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
[TBL] [Abstract][Full Text] [Related]
7. International Experience in Therapeutic Value and Value-Based Pricing: A Rapid Review of the Literature.
Prieto-Pinto L; Garzón-Orjuela N; Lasalvia P; Castañeda-Cardona C; Rosselli D
Value Health Reg Issues; 2020 Dec; 23():37-48. PubMed ID: 32688214
[TBL] [Abstract][Full Text] [Related]
8. Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis.
Obeng-Kusi M; Erstad B; Roe DJ; Abraham I
J Med Econ; 2022; 25(1):894-902. PubMed ID: 35748085
[TBL] [Abstract][Full Text] [Related]
9. Does drug price-regulation affect healthcare expenditures?
Ben-Aharon O; Shavit O; Magnezi R
Eur J Health Econ; 2017 Sep; 18(7):859-867. PubMed ID: 27696009
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan.
Shiroiwa T
Int J Technol Assess Health Care; 2020 Jun; 36(3):270-276. PubMed ID: 32419677
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
Lauenroth VD; Stargardt T
Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
[TBL] [Abstract][Full Text] [Related]
12. Value elements and methods of value-based pricing for drugs in Japan: a systematic review.
Takami A; Kato M; Deguchi H; Igarashi A
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):749-759. PubMed ID: 37339436
[TBL] [Abstract][Full Text] [Related]
13. Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports.
Bloudek LM; Nguyen V; Grueger J; Sullivan SD
Value Health; 2021 Jun; 24(6):789-794. PubMed ID: 34119076
[TBL] [Abstract][Full Text] [Related]
14. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
Persson U; Willis M; Odegaard K
Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
[TBL] [Abstract][Full Text] [Related]
15. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
16. Drug price reform in the UK: debunking the myths.
Thornton S
Health Econ; 2007 Oct; 16(10):981-92. PubMed ID: 17853505
[TBL] [Abstract][Full Text] [Related]
17. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
[TBL] [Abstract][Full Text] [Related]
18. The End of the International Reference Pricing System?
Persson U; Jönsson B
Appl Health Econ Health Policy; 2016 Feb; 14(1):1-8. PubMed ID: 26112982
[TBL] [Abstract][Full Text] [Related]
19. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.
Lipton RB; Brennan A; Palmer S; Hatswell AJ; Porter JK; Sapra S; Villa G; Shah N; Tepper S; Dodick D
J Med Econ; 2018 Jul; 21(7):666-675. PubMed ID: 29571276
[TBL] [Abstract][Full Text] [Related]
20. Is the price right? Paying for value today to get more value tomorrow.
Ramagopalan SV; Diaz J; Mitchell G; Garrison LP; Kolchinsky P
BMC Med; 2024 Jan; 22(1):45. PubMed ID: 38287326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
